Dataset Information

Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.

ABSTRACT: The purpose of this study was to explore whether nontraditional risk factors, such as apolipoprotein C-III (Apo C-III) and its corresponding Apo B lipoprotein (Lp) subclasses, contribute to the risk of cardiovascular disease in rheumatoid arthritis (RA) patients.Apolipoprotein and lipoproteins were measured in 152 RA patients by immunoturbidimetric procedures, electroimmunoassay, and immunoprecipitation. Patients had a coronary artery calcium (CAC) score assessed at baseline and at year 3. Differences in the CAC scores between baseline and year 3 were calculated and dichotomized at 0, where patients with a difference score >0 were denoted as progressors and the rest were denoted as nonprogressors. Differences between means were tested with a 2-sided independent Student's t-test with Satterthwaite's adjustment. Proportion differences were tested with a chi-square test. Multiple logistic regression was performed to assess the relationship between apolipoprotein and lipoprotein levels and the dichotomized CAC score.Progressors accounted for almost 60% of the cohort. Progressors had significantly higher levels of triglycerides, very low-density lipoprotein (VLDL) cholesterol, total cholesterol/high-density lipoprotein (HDL), triglycerides/HDL, Apo B, LpA-II:B:C:D:E, LpB:C, Apo B/Apo A-I, Apo C-III, and Apo C-III-heparin precipitate than the nonprogressors. After adjusting for age, sex, statin use (yes/no), and hypertension (yes/no), significant risk factors of progressors were total cholesterol, triglycerides, VLDL cholesterol, LDL cholesterol, Apo B, LpB:C, Apo C-III, and Apo B/Apo A-I.Apo C-III-containing Apo B lipoprotein subclasses were found to be significantly elevated in progressors compared to nonprogressors. Many of these same lipoproteins were found to be associated with an increase in CAC scores among progressors. These lipoproteins may be considered new risk factors for progression of atherosclerosis in RA patients.

SUBMITTER: Knowlton N

PROVIDER: S-EPMC3552355 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.

Knowlton N N Wages J A JA Centola M B MB Giles J J Bathon J J Quiroga C C Alaupovic P P

Arthritis care & research 20120701 7

<h4>Objective</h4>The purpose of this study was to explore whether nontraditional risk factors, such as apolipoprotein C-III (Apo C-III) and its corresponding Apo B lipoprotein (Lp) subclasses, contribute to the risk of cardiovascular disease in rheumatoid arthritis (RA) patients.<h4>Methods</h4>Apolipoprotein and lipoproteins were measured in 152 RA patients by immunoturbidimetric procedures, electroimmunoassay, and immunoprecipitation. Patients had a coronary artery calcium (CAC) score assesse ...[more]

PMID: 22337612

Similar Datasets

Project description:BACKGROUND AND AIMS:Non-high-density (HDL)-cholesterol, low-density lipoprotein (LDL)-particle number, apolipoprotein B, lipoprotein(a) (Lp(a)), and small-dense (sdLDL) and large-buoyant (lbLDL) LDL-subfractions are emerging apo B-containing atherosclerotic cardiovascular disease (ASCVD) risk factors. Current guidelines emphasize lifestyle, including weight loss, for ASCVD risk management. Whether weight change affects these emerging risk factors beyond that predicted by traditional triglyceride and LDL-cholesterol measurements remains to be determined. METHOD:Regression analyses of fasting ?apo B-containing lipoproteins vs. ?BMI were examined in a large anonymized clinical laboratory database of 33,165 subjects who did not report use of lipid-lowering medications. Regression slopes (±SE) were estimated as: *?mmol/L per ?kg/m2, †?g/L per ?kg/m2, ‡?% per ?kg/m2, and §??mol/L per ?kg/m2. RESULTS:When adjusted for age, ?BMI was significantly related to ?nonHDL-cholesterol (males: 0.0238?±?0.0041, P?=?7.9?×?10-?9; females: 0.0330?±?0.0037, P?<?10-?16)*, ?LDL-particles (males: 0.0128?±?0.0024, P?=?2.1?×?10-?7; females: 0.0114?±?0.0022, P?=?3.2?×?10-?7)*, ?apo B (males: 0.0053?±?0.0010, P?=?7.9?×?10-?8; females: 0.0073?±?0.0009, P?=?2.2?×?10-?16)†, ?sdLDL (males: 0.0125?±?0.0015, P?=?2.2?×?10-?16; females: 0.0128?±?0.0012, P?<?10-?16)*, ?percent LDL carried on small dense particles (%sdLDL, males: 0.296?±?0.035, P?<?10-?16; females: 0.221?±?0.023, P?<?10-?16)‡, ?triglycerides (males: 0.0358?±?0.0049, P?=?2.0?×?10-?13; females: 0.0304?±?0.0029, P?<?10-?16)*, and ?LDL-cholesterol (males: 0.0128?±?0.0034, P?=?0.0002; females: 0.0232?±?0.0031, P?=?1.2?×?10-?13)* in both males and females. Age-adjusted ?BMI was significantly related to ?lbLDL in females (0.0098?±?0.0024, P?=?3.9?×?10-?5)* but not males (0.0007?±?0.0026, P?=?0.78)*. Female showed significantly greater increases in ?LDL-cholesterol (P?=?0.02) and ?lbLDL (P?=?0.008) per ?BMI than males. ?BMI had a greater effect on ?LDL-cholesterol measured directly than indirect estimate of ?LDL-cholesterol from the Friedewald equation. When sexes were combined and adjusted for age, sex, ?triglycerides and ?LDL-cholesterol, ?BMI retained residual associations with ?nonHDL-cholesterol (0.0019?±?0.0009, P?=?0.03)*, ?LDL-particles (0.0032?±?0.0010, P?=?0.001)*, ?apo B (0.0010?±?0.0003, P?=?0.0008)†, ?Lp(a) (-?0.0091?±?0.0021, P?=?1.2?×?10-?5)§, ?sdLDL (0.0001?±?0.0000, P?=?1.6?×?10-?11)* and ?%sdLDL (0.151?±?0.018, P?<?10-?16) ‡. CONCLUSIONS:Emerging apo B-containing risk factors show associations with weight change beyond those explained by the more traditional triglyceride and LDL-cholesterol measurements.

Project description:Objectives: Periodontal disease (PD) and rheumatoid arthritis (RA) are known chronic conditions with sustained inflammation leading to osteolysis. Cardiovascular diseases (CVD) are frequent comorbidities that may arise from sustained inflammation associated with both PD and RA. In order to determine CVD risk, alterations at the molecular level need to be identified. The objective of this study, therefore, was to assess the relationship of CVD associated biomarkers in RA patients and how it is influenced by PD. Methods: The study consisted of patient (26 RA with PD, 21 RA without PD, 51 patients with PD only) and systemically and periodontally healthy control (n = 20) groups. Periodontal parameters bleeding on probing, probing pocket depth, and marginal bone loss were determined to characterize the patient groups. Proteomic analysis of 92 CVD-related protein biomarkers was performed using a multiplex proximity extension assay. Biomarkers were clustered using the search tool for retrieval of interacting genes (STRING) to determine protein−protein interaction (PPI) networks. Results: RA patients with PD had higher detection levels for 47% of the measured markers (ANGPT1, BOC, CCL17, CCL3, CD4, CD84, CTRC, FGF-21, FGF-23, GLO1, HAOX1, HB-EGF, hOSCAR, HSP 27, IL16, IL-17D, IL18, IL-27, IL6, LEP, LPL, MERTK, MMP12, MMP7, NEMO, PAPPA, PAR-1, PARP-1, PD-L2, PGF, PIgR, PRELP, RAGE, SCF, SLAMF7, SRC, THBS2, THPO, TNFRSF13B, TRAIL-R2, VEGFD, VSIG2, and XCL1) as compared to RA without PD. Furthermore, a strong biological network was identified amongst these proteins (clustering coefficient = 0.52, PPI enrichment p-value < 0.0001). Coefficients for protein clusters involved in CVD (0.59), metabolic (0.53), and skeletal (0.51) diseases were strongest in the PD group. Conclusion: Periodontal disease augments CVD-related biomarkers in RA through shared pathological clusters, concurrently enhancing metabolic and skeletal disease protein interactions, independent of autoimmune status.

Dataset Information

Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.

Publications

Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets